8-K: Eyenovia Implements 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance

Eyenovia, Inc. has enacted a 1-for-80 reverse stock split to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Summary

• Eyenovia, Inc. implemented a 1-for-80 reverse stock split of its common stock, effective January 31, 2025, at 4:00 p.m. Eastern Time.
• The reverse stock split was undertaken to regain compliance with the minimum bid price required for listing on the Nasdaq Capital Market.
• Every 80 shares of issued and outstanding common stock were combined into one share.
• No fractional shares were issued; instead, stockholders entitled to a fractional share will receive a cash payment.
• The reverse stock split uniformly affected all stockholders and did not alter their percentage ownership interests, except for the cash payments for fractional shares.
• The par value of the common stock remained unchanged, and the rights and preferences of the common stock were not modified.
• The common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on February 3, 2025, under the symbol EYEN with a new CUSIP number of 30234E 203.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is taking action to maintain its listing, the need for a reverse stock split suggests underlying financial challenges. The forward-looking statements also highlight risks and uncertainties.

Positives

• The reverse stock split aims to ensure continued listing on the Nasdaq Capital Market, which could improve investor confidence.
• The company is addressing compliance issues proactively.

Negatives

• The reverse stock split was necessary to regain compliance with Nasdaq listing requirements, indicating previous struggles with maintaining the minimum bid price.
• Reverse stock splits can sometimes be perceived negatively by investors as they often signal underlying financial difficulties.

Risks

• There is no guarantee that the reverse stock split will be sufficient to maintain compliance with Nasdaq listing requirements in the long term.
• The company's future performance is subject to risks and uncertainties that could affect its ability to maintain its listing.

Future Outlook

The company's ability to regain and maintain compliance with Nasdaq listing rules is uncertain and subject to various risks and factors.

Management Comments

• The company filed the Amendment to enable the Company to regain compliance with the minimum bid price required to remain listed on the Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. Other companies in the biotech or pharmaceutical sectors facing similar challenges may consider this approach.

Comparison to Industry Standards

• Many small-cap biotech companies with promising but yet-to-be-commercialized products face similar challenges with maintaining share price compliance.
• A comparable example is when Delcath Systems, Inc. implemented a reverse stock split to maintain its Nasdaq listing.
• The success of Eyenovia's reverse stock split will depend on its ability to execute its business plan and achieve commercial success with its products, similar to how other companies in the sector have navigated such situations.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but their percentage ownership (excluding fractional shares) will remain the same.
• The reverse stock split aims to maintain the company's listing, which could benefit shareholders in the long term.
• Employees may be affected by the company's overall financial performance and ability to execute its business plan.

Next Steps

• The company will begin trading on a split-adjusted basis on February 3, 2025.
• The company will monitor its share price to ensure continued compliance with Nasdaq listing requirements.

Key Dates